Our data demonstrate that in these cells, temsirolimus treatment promotes a further increase in Akt phosphorylation, indicating that signaling through the pro-survival PI3K/Akt pathway is likely how these endometrial cancer cell lines eventually circumvent mTOR inhibition. This evidence concerns the gene AKT1 and endometrial cancer.